| Characteristic | New Mechanism | Orphan | Existing Mechanism |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
The chart is not accessible to screen readers. Please switch to the table view to access the data.
Download
Source
Source
Release date
April 2016
More information
Region
United States
Survey time period
2003 to 2015
Supplementary notes
New Molecular Entity (NME): A novel molecular or biologic
entity or combination where at least one element is novel.
This statistic was assembled from several IMS Health reports.
NME launches in the U.S. by year of launch, regardless of timing of FDA approval.
New mechanism: First product with a new mechanism of action for its FDA approved indication.
Orphan: Drugs with one or more orphan indications
approved by FDA at launch.
Existing mechanism: Subsequent products with an existing mechanism of action for an indication.
Citation formats
